Well-known cancer gene NRAS produces five variants, study finds

April 7, 2014

A new study shows that a gene discovered 30 years ago and now known to play a fundamental role in cancer development produces five different gene variants (called isoforms), rather than just the one original form, as thought.

The study of the NRAS gene by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) identified four previously unknown variants that the NRAS gene produces.

The finding might help improve drugs for cancers in which aberrant activation of NRAS plays a crucial role. It also suggests that NRAS might affect additional target molecules in cells, the researchers say.

The isoforms show striking differences in size, abundance and effects. For example, the historically known protein (isoform 1) is 189 amino-acids long, while one of the newly discovered variants, isoform 5, is only 20 amino-acids long.

The study is published in the Proceedings of the National Academy of Sciences.

"We believe that the existence of these isoforms may be one reason why NRAS inhibitors have so far been unsuccessful," says corresponding author Albert de la Chapelle, MD, PhD, professor of Medicine and the Leonard J. Immke Jr. and Charlotte L. Immke Chair in Cancer Research.

Co-senior author Clara D. Bloomfield, MD, Distinguished University Professor and Ohio State University Cancer Scholar, notes that one of the newly discovered isoforms might play a greater role in the development of some cancers than the known protein itself.

"Targeting the NRAS pathway may have been unsuccessful in the past because we were unaware of the existence of additional targets of these novel isoforms," says Bloomfield, who is also senior adviser to the OSUCCC – James and holds the William Greenville Pace III Endowed Chair in Cancer Research.

"The discovery of these isoforms might open a new chapter in the study of NRAS," says first author Ann-Kathrin Eisfeld, MD, a postdoctoral fellow in the laboratories of de la Chapelle and of Bloomfield. "Knowing that these isoforms exist may lead to the development of drugs that specifically decrease or increase the expression of one of them and provide more effective treatment for patients."

For this study, de la Chapelle, Eisfeld and their colleagues analyzed expression of the NRAS isoforms in a variety of normal and matched tumor samples. Key technical findings include:

  • The isoforms showed modest but significant differences in expression in normal and malignant samples;
  • Each isoform had different effects on NRAS target molecules;
  • Isoform 5 was the most aggressive variant in proliferation and transformation assays;
  • Isoforms 3 and 5, the smallest of the isoforms (40 and 20 amino acids respectively), were found in both the cell nucleus and cytoplasm.

Explore further: Proteins in histone group might influence cancer development, study shows

More information: Paper: NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation, www.pnas.org/content/early/201 … /1401727111.abstract

Related Stories

Proteins in histone group might influence cancer development, study shows

September 3, 2013
Spool-like proteins called histones play a crucial role in packaging the nearly seven feet of DNA found in most human cells. A new study shows that a group of histones that are thought to behave the same way actually are ...

Scientists develop gene test to accurately classify brain tumors

February 18, 2014
Scientists at The Wistar Institute have developed a mathematical method for classifying forms of glioblastoma, an aggressive and deadly type of brain cancer, through variations in the way these tumor cells "read" genes. Their ...

Tipping the balance between senescence and proliferation

November 15, 2013
An arrest in cell proliferation, also referred to as cellular senescence, occurs as a natural result of aging and in response to cellular stress. Senescent cells accumulate with age and are associated with many aging phenotypes, ...

Researchers survey protein family that helps the brain form synapses

March 18, 2014
Neuroscientists and bioengineers at Stanford are working together to solve a mystery: how does nature construct the different types of synapses that connect neurons—the brain cells that monitor nerve impulses, control muscles ...

Multiple 'siblings' from every gene: Alternate gene reading leads to alternate gene products

July 11, 2011
A genome-wide survey by researchers at The Wistar Institute shows how our cells create alternate versions of mRNA transcripts by altering how they "read" DNA. Many genes are associated with multiple gene promoters, the researchers ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.